Virax Biolabs Group Limited (VRAX)
After hours:
| Previous Close | 0.6450 |
| Open | 0.6740 |
| Bid | 0.6278 x 100 |
| Ask | 0.8918 x 100 |
| Day's Range | 0.6524 - 0.8285 |
| 52 Week Range | 0.6000 - 5.4500 |
| Volume | |
| Avg. Volume | 35,426 |
| Market Cap | 1.724M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -17.7000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
PR NewswireVirax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the launch of ImmuneSelect ("ImmuneSelect") within the ViraxImmune™ T-Cell diagnostic platform for research-use-only ("RUO"), at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) Congress, which is taking place from April 27th to April 30th, 2024, in Barcelo
- PR Newswire
Virax Biolabs to Participate at ESCMID Global 2024
Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it will be hosting a booth at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) on April 27-30, 2024, in Barcelona, Spain.
- PR Newswire
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") dated March 13, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2)(the "Minimum Bid Price Rule") for continued listing on the NASDAQ.
